Hypercholesterolemia Clinical Trial
Official title:
An Open-Label Extension Study to Assess the Long-term Safety and Efficacy of Mipomersen in Subjects With Familial Hypercholesterolemia
The purpose of this study is to evaluate the safety and efficacy of extended dosing of mipomersen in patients with familial hypercholesterolemia on lipid-lowering therapy who have completed either the 301012-CS8 (NCT00280995) or 301012-CS9 (NCT00281008) clinical drug trials.
Familial Hypercholesterolemia (FH) is an autosomal dominant metabolic disorder characterized
by markedly elevated low density lipoprotein (LDL), premature onset of atherosclerosis, and
development of xanthomata. There are two distinct subpopulations that have a high unmet
medical need due to the lack of alternative therapy: homozygotes, who have two defective LDL
receptor (LDL-R) genes, and heterozygotes with a history of cardiovascular disease (CVD) on
maximally tolerated therapy. Treatment for FH is directed at lowering plasma levels of
LDL-C.
Mipomersen is an antisense drug targeted to human apolipoprotein B (apoB), the principal
apolipoprotein of atherogenic LDL-C and its metabolic precursor, very low density
lipoprotein (VLDL). Mipomersen is complimentary to the coding region of the messenger
ribonucleic acid (mRNA) for apo-B. Inhibition of apo-B would be expected to impair VLDL
synthesis and result in lowered levels of LDL-C.
In early clinical trials, mipomersen has been shown to reduce levels of LDL-C to recommended
target levels in some participants.
This was an open-label extension study, which consisted of a ≤2-week screening period, up to
3 years of treatment with mipomersen, and a 24-week post-treatment follow-up period.
Patients who participated in Cohorts A, B, or C in study 301012-CS9 were randomized in a 1:1
ratio to mipomersen 200 mg once a week (QW) or 200 mg mipomersen every other week (QOW) for
up to 3 years. Patients randomized to mipomersen 200 mg QOW were allowed to receive
mipomersen 200 mg QW at the Investigator's discretion after the first 52 weeks of the
treatment period. Patients who participated in study 301012-CS8 or Cohort D of study
301012-CS9 received 200 mg mipomersen QW for up to 3 years.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Recruiting |
NCT03947866 -
Ezetimibe-Rosuvastatin Evaluation Study
|
||
Completed |
NCT01709513 -
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
|
Phase 3 | |
Completed |
NCT01212900 -
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
|
Phase 4 | |
Completed |
NCT00001154 -
Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
|
||
Completed |
NCT02550288 -
A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)
|
Phase 3 | |
Completed |
NCT03929198 -
Translation of Pritikin Program to the Community
|
N/A | |
Completed |
NCT04485793 -
Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia
|
N/A | |
Completed |
NCT02341924 -
Validating the "Foods for Health" Portfolio of Functional Food Products
|
N/A | |
Active, not recruiting |
NCT02223793 -
Vascular Lifestyle-Intervention and Screening in Pharmacy
|
N/A | |
Completed |
NCT01934608 -
The Effect of Synching Prescription Refills on Adherence
|
N/A | |
Completed |
NCT01941836 -
Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients
|
Phase 2 | |
Recruiting |
NCT01705873 -
Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen
|
N/A | |
Completed |
NCT01670734 -
Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01678521 -
Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients
|
N/A | |
Completed |
NCT01370603 -
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)
|
Phase 3 | |
Completed |
NCT01370590 -
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)
|
Phase 3 | |
Completed |
NCT01575171 -
Using Nudges to Implement Comparative Effectiveness
|
N/A | |
Completed |
NCT01446679 -
Special Drug Use-Results Survey of Lipitor Tablets
|
N/A | |
Completed |
NCT01768403 -
Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia
|
N/A |